Pathogenesis of COVID-19. Role of heparins in the therapy of severe conditions in patients with COVID-19


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The novel viral disease and its associated severe acute respiratory syndrome are currently the world's most significant public health crisis. The main stages of alveolar injury are mediated by endothelial damage, which leads to the release of cytokines and chemokines, the recruitment of immune cells, and the activation of the coagulation system and thrombosis. Numerous studies, including autopsy and histological data, confirm endothelial dysfunction in coronavirus infection and note an increased risk of venous thromboembolic events in patients with a severe course. Increases in D-dimer and fibrinogen degradation products remain to be the main prognostically important laboratory criteria, correlating with a higher risk of severe disease and mortality. Taking into account the presence of coagulopathy, heparins may be effective and affordable drugs for reducing the risk of severe acute respiratory syndrome. Low-molecular-weight heparins reduce the release and activity of IL-6 that is responsible for the development of cytokine storm, which is associated with better outcomes in patients with severe COVID-19. In addition, the antiviral and anti-inflammatory activity of heparins should be taken into consideration, which is very important for leveling the release of pro-inflammatory cytokines and mitigating the damaging effect of the virus on the endothelium. Conclusion. At this stage of understanding the pathophysiology of coronavirus infection, it is worth considering the use of low-molecular-weight heparins in patients with severe COVID-19, including those with sepsis-induced coagulopathy. The use of heparins in a therapeutic dosage has shown a significantly greater efficacy than that in prophylactic doses.

Full Text

Restricted Access

About the authors

Dina R. Eremeeva

Academician I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of the Russian Federation; Professor V.F. Snegirev Maternity Hospital No 6

Email: dina-bikmullina@yandex.ru
Cand. Med. Sci., Assistant of the Department of Obstetrics, Gynecology and Reproductology

Vitaly F. Bezhenar

First St. Petersbu

Email: bezvitaly@yandex.ru
Dr. Med. Sci., Professor, Head of the Departments of Obstetrics, Gynecology and Neonatology/Reproductology

Marina S. Zainulina

Academician I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of the Russian Federation; Professor V.F. Snegirev Maternity Hospital No 6

Email: zainulina@yandex.ru
Dr. Med. Sci., Professor of the Department of Obstetrics, Gynecology and Reproductology

Yulia S. Globa

Academician I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of the Russian Federation

Email: globa410888@mail.ru
Clinical Resident of the Department of Obstetrics, Gynecology and Reproductology

References

  1. Временные методические рекомендации «Медицинская реабилитация при новой коронавирусной инфекции (COVID-19)». Версия 2. (утв. Министерством здравоохранения РФ 31.07.2020.) 2020. [Temporary guidelines. Medical rehabilitation for new coronavirus infection (COVID-19). Version 2 (07/31/2020). Ministry of Health of the Russian Federation. (in Russian)].
  2. Беженарь В.Ф., Айламазян Э.К., Зазерская И.Е., Иванов Д.О., Аракелян Б.В., Баутин А.Е. и др. Краткие клинические рекомендации. Тактика ведения беременных, рожениц и родильниц с подозрением или подтвержденной инфекцией COVID-19. МКБ-10: U07.2, U07.1. Версия 1.0 от 14.04.2020. Санкт-Петербург: Эко-Вектор; 2020.
  3. Labo N., Ohnuki H., Tosato G. Vasculopathy and coagulopathy associated with SARS-CoV-2 infection. Cells. 2020; 9(7): 1583. https://dx.doi.org/10.3390/ cells9071583.
  4. Ferner R.E., Levi M., Sofat R., Aronson J.K. Thrombosis in COVID-19: clinical outcomes, biochemical and pathological changes, and treatments. Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences University of Oxford; June 4 2020.
  5. Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 2020; 383(2): 120-8. https://dx.doi.org/10.1056/ NEJMoa2015432.
  6. Costanzo L., Palumbo F.P., Ardita G., Antignani P.L., Arosio E., Failla G. Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia. J. Vasc. Surg. Venous Lymphat. Disord. 2020; 8(5): 711-6. https://dx.doi.org/10.1016/j.jvsv.2020.05.018.
  7. Amraei R., Rahimi N. COVID-19, renin-angiotensin system and endothelial dysfunction. Cells. 2020; 9(7): 1652. https://dx.doi.org/10.3390/cells9071652.
  8. Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395(10234): 1417-8. https://dx.doi.org/10.1016/S0140-6736(20)30937-5.
  9. Jung F., Kruger-Genge A., Franke R.P., Hufert F., Kupper J.-H. COVID-19 and the endothelium. Clin. Hemorheol. Microcirc. 2020; 75(1): 7-11. https://dx.doi. org/10.3233 / CH-209007.
  10. Cao B. Chinese Cardiovascular Association and American College of Cardiology, cosponsors. March 19, 2020. Available at: https://youtu.be/CjEhV68GcD8 Accessed March 19 2020.
  11. Wichmann D., Sperhake J.P., LUtgehetmann M., Steurer S., Edler C, Heinemann A. et al. Autopsy findings and venous thromboembolism in patients with COVID-19: A prospective cohort study. Ann. Intern. Med. 2020; 173(4): 268-77. https://dx.doi.org/10.7326/M20-2003.
  12. Panigada M., Bottino N., Tagliabue P., Grasselli G., Novembrino C., Chantarangkul V., Pesenti A. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J. Thromb. Haemost. 2020; 18(7): 1738-42. https:// dx.doi.org/10.1111/jth.14850.
  13. Menter T., Haslbauer J.D., Nienhold R., Savic S., Hopfer H., Deigendesch N. et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Hystopathology. 2020; 77(2): 198-209. https:// dx.doi.org/10.1111/his.14134.
  14. Cheng Y., Luo R., Wang K., Zhang M., Wang Z., Dong L. et al. Kidney disease is associated with in-hospital death of patients with COVID 19. Kidney Int. 2020; 97(5): 829-38. https://dx.doi.org/10.1016/ j.kint.2020.03.005
  15. Iba T., Levy J.H., Levi M., Connors J.M., Thachil J. Coagulopathy of coronavirus disease 2019. Crit. Care Med. 2020; 48(9):1358-64. https://dx.doi.org/10.1097/ CCM.0000000000004458.
  16. Colmenero I., Santonja C., Alonso-Riano M., Noguera-Morel L., Hernandez-Martin A., Andina D. et al. SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultraestructural study of 7 paediatric cases. Br. J. Dermatol. 2020; 183(4): 729-37. https:// dx.doi.org/10.1111/bjd.19327.
  17. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020; 395(10229): 1054-62. https://dx.doi. org/10.1016/S0140-6736(20)30566-3.
  18. Hippensteel J.A., La Riviere W.B., Colbert J.F. Heparin as a therapy for COVID-19: current evidence and future possibilities. Am. J. Physiol. Lung Cell. Mol. Physiol. 2020; 319(2): L211-7. https://dx.doi.org/10.1152/ ajplung.00199.2020.
  19. Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020; 18(5): 1094-9. https://dx.doi. org/10.1111/jth.14817.
  20. Perna A.F., Capolongo G., Trepiccione F., Simeoni M., Zacchia M., Ingrosso D. COVID-19, low-molecular-weight heparin, and hemodialysis. Kidney Blood Press. Res. 2020; 45(3): 357-62. https://dx.doi.org/10.1159/000508460.
  21. Shi C., Wang C., Wang H., Yang C., Cai F., Zeng F. et al. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study. Clin. Transl. Sci. 3 September 2020. https://dx.doi.org/10.1111/cts.12880.
  22. Trinh M., Chang D.R., Govindarajulu U.S., Kane E., Fuster V., Kohli-Seth R., Ahmed S. Therapeutic anticoagulation is associated with decreased mortality in mechanically ventilated COVID-19 patients. medRxiv preprint. https://dx.doi. org/10.1101/2020.05.30.20117929.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media